ELMWOOD PARK, N.J.--(BUSINESS WIRE)--Based on its recent analysis of the clinical diagnostics market, Frost & Sullivan recognized GenPath Diagnostics, a business unit of BioReference Laboratories, Inc ...

Cambridge-based GenPath Pharmaceuticals Inc., a drug discovery and development company focused on the treatment of cancer and other diseases, announced today that it has entered into a multi-year ...

Bio-Reference Laboratories, Inc. has announced that K-ras mutation testing for patients with metastatic colorectal (mCRC) or non-small-cell lung (NSCLC) cancers will now be available through the ...

ELMWOOD PARK, N.J.--(BUSINESS WIRE)--Bio-Reference Laboratories, Inc. (“BRLI”) (NASDAQ: BRLI) announced today that it has completed an equity investment in InCellDx, Inc. (“InCellDx”), a privately ...

ELMWOOD PARK, N.J.--(BUSINESS WIRE)-- BioReference Laboratories, Inc. (NASDAQ: BRLI) and its GenPath Oncology business unit and through its exclusive commercialization agreement with the Massachusetts ...

Ariosa's non invasive prenatal screening (NIPS) test, the Harmony Prenatal Test, is one of the most widely studied tests utilized in prenatal screening. The test has been performed in over 1.5 million ...

Less than a month after raising $42.7 million in a Series B round, GenPath Pharmaceuticals Inc. said it has nailed down a multiyear cancer deal with Merck & Co. Inc. worth up to $100 million, ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Cambridge-based GenPath Pharmaceuticals Inc., a company ...

CAMBRIDGE, Mass. -- Closely held GenPath Pharmaceuticals Inc. said it signed a multiyear agreement with Merck & Co. covering its cancer-research techniques that has a potential value of $100 million ...

GenPath Pharmaceuticals Inc., Cambridge, Mass., raised $15.5 million in a Series A financing. The round was led by MPM Capital and joined by Venrock Associates, Prospect Venture Partners, Greylock and ...